Spironolactone for Left Ventricular Hypertrophy

Primary Indication: Resistant Hypertension with LVH

The American College of Cardiology recommends adding spironolactone 25 mg daily to the antihypertensive regimen of patients with resistant hypertension and left ventricular hypertrophy, as it provides superior LVH regression compared to ACE inhibitors alone, particularly in patients with elevated serum procollagen type III amino-terminal peptide levels 1
The European Society of Cardiology suggests that spironolactone is specifically recommended for refractory hypertensive patients as an additional agent when blood pressure remains uncontrolled on multiple medications 1, 2
In resistant hypertension, spironolactone at 25-50 mg daily provides significant additional blood pressure reduction when added to multidrug regimens 2
The American College of Cardiology/American Heart Association guidelines note that eplerenone, in synergy with enalapril, has demonstrated reduction in LV mass 1

Before initiating spironolactone for LVH, verify that serum potassium is <5.0 mEq/L and serum creatinine is <2.5 mg/dL, according to the American College of Cardiology 1, 3
The patient should already be on optimal doses of ACE inhibitor or ARB and beta-blocker, as recommended by the European Society of Cardiology 3
Exclude primary aldosteronism if clinically suspected, though the good response to low-dose spironolactone may occur in both primary and secondary aldosteronism, as noted by the European Heart Journal 2

Start spironolactone at 12.5-25 mg once daily and titrate to 25-50 mg daily after 4-8 weeks if tolerated, as recommended by the Praxis Medical Insights 3
Check potassium and creatinine within 3 days of initiation, at 1 week, monthly for 3 months, then every 3 months thereafter, according to the Praxis Medical Insights 3

If your patient has symptomatic heart failure with reduced ejection fraction (HFrEF, LVEF ≤35-40%) and LVH, spironolactone becomes a Class I recommendation with proven mortality benefit, as recommended by the European Society of Cardiology 4, 3
In the RALES trial, spironolactone reduced all-cause mortality by 30% and heart failure hospitalization by 35% in patients with severe HF, as reported by the European Heart Journal 4
In the EMPHASIS-HF trial, eplerenone reduced cardiovascular death or HF hospitalization by 37% in patients with mild symptoms (NYHA Class II), as noted by the European Heart Journal 4

Do not combine spironolactone with other potassium-sparing diuretics (amiloride, triamterene), as hyperkalemia risk increases dramatically, as warned by the Praxis Medical Insights 3
Hyperkalemia risk is particularly elevated when spironolactone is combined with ACE inhibitors or ARBs, which is the typical clinical scenario, as noted by the Praxis Medical Insights 3
Attention to serum potassium and creatinine is mandatory because many patients with resistant hypertension have underlying renal dysfunction, as highlighted by the European Heart Journal 2